{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:49:00Z","timestamp":1782773340915,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiogenesis is essential for tumor development and growth. Vascular endothelial growth factor-A (VEGF-A), a key regulator of angiogenesis, has several isoforms; however, their expression patterns and mechanisms of action are not fully understood. In this study, we aimed to investigate the expression patterns of VEGF-A isoforms and their effects on endothelial cell responses related to angiogenesis under hypoxic and low-glucose conditions, which are major features of the tumor microenvironment, using a hepatocellular carcinoma cell line (HepG2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We cultured human liver cancer-derived cell lines under hypoxic and low-glucose conditions and analyzed the expression patterns of VEGF-A isoforms using an original enzyme-linked immunosorbent assay system that could separately detect human VEGF-A121 and VEGF-A165, which we had previously developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The addition of low-glucose conditions to a hypoxic environment increased\n                      <jats:italic>VEGF-A<\/jats:italic>\n                      mRNA and protein expression in HepG2 cells, particularly that of VEGF-A165. Since it is known that AMP-activated protein kinase (AMPK)\/p38 mitogen-activated protein kinase (p38 MAPK) signaling increases the stability of\n                      <jats:italic>VEGF-A<\/jats:italic>\n                      mRNA, we investigated the involvement of this signal and found that activation of AMPK increased VEGF-A165 protein expression, while inhibition of AMPK and p38 MAPK reduced VEGF-A165 protein expression. Furthermore, the effects of VEGF-A isoforms on human umbilical vein endothelial cells (HUVECs) were examined. VEGF-A165 activated phosphorylation signals in HUVECs and upregulated their proliferation and migration abilities compared to VEGF-A121.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that AMPK\/p38 MAPK signaling selectively enhances hypoxia-inducible factor-induced VEGF-A165 expression in tumors and promotes endothelial cell proliferation and migration, which may contribute to angiogenesis in vivo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16069-0","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:24:52Z","timestamp":1778041492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AMPK\/p38 MAPK signaling selectively enhances HIF-induced VEGF-A165 expression under hypoxic and low-glucose conditions in HepG2 cells to promote endothelial cell proliferation and migration"],"prefix":"10.1186","volume":"26","author":[{"given":"Hirohito","family":"Hashinokuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munekazu","family":"Yamakuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayuki","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Tabaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonori","family":"Tanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Okawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminori","family":"Namino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruto","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"16069_CR1","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. 2014;87:20130676.","journal-title":"Br J Radiol"},{"key":"16069_CR2","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92:5510\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"16069_CR3","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1074\/jbc.M010144200","volume":"276","author":"C Chen","year":"2001","unstructured":"Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001;276:9519\u201325.","journal-title":"J Biol Chem"},{"key":"16069_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1101\/gad.12.2.149","volume":"12","author":"NV Iyer","year":"1998","unstructured":"Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149\u201362.","journal-title":"Genes Dev"},{"key":"16069_CR5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956;123:309\u201314.","journal-title":"Science"},{"key":"16069_CR6","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s13046-020-01709-5","volume":"39","author":"X Jiang","year":"2020","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Zhang S, Gong Z, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39:204.","journal-title":"J Exp Clin Cancer Res"},{"key":"16069_CR7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385\u2013403.","journal-title":"Nat Rev Drug Discov"},{"key":"16069_CR8","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nature04480","volume":"438","author":"K Alitalo","year":"2005","unstructured":"Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438:946\u201353.","journal-title":"Nature"},{"key":"16069_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2005-05-2047","volume":"107","author":"AK Malik","year":"2006","unstructured":"Malik AK, Baldwin ME, Peale F, Fuh G, Liang WC, Lowman H, et al. Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood. 2006;107:550\u20137.","journal-title":"Blood"},{"key":"16069_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039\u201349.","journal-title":"N Engl J Med"},{"key":"16069_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1091\/mbc.e09-07-0590","volume":"21","author":"N Ferrara","year":"2010","unstructured":"Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 2010;21:687\u201390.","journal-title":"Mol Biol Cell"},{"key":"16069_CR12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1091\/mbc.4.12.1317","volume":"4","author":"JE Park","year":"1993","unstructured":"Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. 1993;4:1317\u201326.","journal-title":"Mol Biol Cell"},{"key":"16069_CR13","doi-asserted-by":"publisher","first-page":"7788","DOI":"10.1074\/jbc.271.13.7788","volume":"271","author":"BA Keyt","year":"1996","unstructured":"Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, et al. The carboxyl-terminal domain (111\u2013165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996;271:7788\u201395.","journal-title":"J Biol Chem"},{"key":"16069_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1242\/bio.017434","volume":"5","author":"GW Fearnley","year":"2016","unstructured":"Fearnley GW, Smith GA, Abdul-Zani I, Yuldasheva N, Mughal NA, Homer-Vanniasinkam S, et al. VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking and proteolysis. Biol Open. 2016;5:571\u201383.","journal-title":"Biol Open"},{"key":"16069_CR15","first-page":"1482","volume":"28","author":"T Pufe","year":"2001","unstructured":"Pufe T, Petersen W, Tillmann B, Mentlein R. Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J Rheumatol. 2001;28:1482\u20135.","journal-title":"J Rheumatol"},{"key":"16069_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3109\/08977199509003209","volume":"12","author":"M Bacic","year":"1995","unstructured":"Bacic M, Edwards NA, Merrill MJ. Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors. 1995;12:11\u20135.","journal-title":"Growth Factors"},{"key":"16069_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2013.11.002","volume":"25","author":"P Vempati","year":"2014","unstructured":"Vempati P, Popel AS, Mac GF. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning. Cytokine Growth Factor Rev. 2014;25:1\u201319.","journal-title":"Cytokine Growth Factor Rev"},{"key":"16069_CR18","doi-asserted-by":"publisher","first-page":"e4915","DOI":"10.7717\/peerj.4915","volume":"6","author":"MS Chesnokov","year":"2018","unstructured":"Chesnokov MS, Khesina PA, Shavochkina DA, Kustova IF, Dyakov LM, Morozova OV, et al. Shift in VEGFA isoform balance towards more angiogenic variants is associated with tumor stage and differentiation of human hepatocellular carcinoma. PeerJ. 2018;6:e4915.","journal-title":"PeerJ"},{"key":"16069_CR19","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/ijc.30567","volume":"140","author":"M Canavese","year":"2017","unstructured":"Canavese M, Ngo DT, Maddern GJ, Hardingham JE, Price TJ, Hauben E. Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. Int J Cancer. 2017;140:2183\u201391.","journal-title":"Int J Cancer"},{"key":"16069_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clinbiochem.2012.01.025","volume":"45","author":"C Parisi","year":"2012","unstructured":"Parisi C, Markou A, Lianidou ES. Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants. Clin Biochem. 2012;45:475\u201382.","journal-title":"Clin Biochem"},{"key":"16069_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1534735405282557","volume":"4","author":"CR Pradeep","year":"2005","unstructured":"Pradeep CR, Sunila ES, Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr Cancer Ther. 2005;4:315\u201321.","journal-title":"Integr Cancer Ther"},{"key":"16069_CR22","doi-asserted-by":"publisher","first-page":"e9575","DOI":"10.1371\/journal.pone.0009575","volume":"5","author":"R Ghosh","year":"2010","unstructured":"Ghosh R, Lipson KL, Sargent KE, Mercurio AM, Hunt JS, Ron D, et al. Transcriptional regulation of VEGF-A by the unfolded protein response pathway. PLoS ONE. 2010;5:e9575.","journal-title":"PLoS ONE"},{"key":"16069_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2199-14-27","volume":"14","author":"J Terashima","year":"2013","unstructured":"Terashima J, Tachikawa C, Kudo K, Habano W, Ozawa S. An aryl hydrocarbon receptor induces VEGF expression through ATF4 under glucose deprivation in HepG2. BMC Mol Biol. 2013;14:27.","journal-title":"BMC Mol Biol"},{"key":"16069_CR24","doi-asserted-by":"publisher","first-page":"e0284131","DOI":"10.1371\/journal.pone.0284131","volume":"18","author":"M Yamakuchi","year":"2023","unstructured":"Yamakuchi M, Okawa M, Takenouchi K, Bibek A, Yamada S, Inoue K, et al. VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals. PLoS ONE. 2023;18:e0284131.","journal-title":"PLoS ONE"},{"key":"16069_CR25","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2174\/092986712803413944","volume":"19","author":"A Ahluwalia","year":"2012","unstructured":"Ahluwalia A, Tarnawski AS. Critical role of hypoxia sensor--HIF-1\u03b1 in VEGF gene activation, implications for angiogenesis and tissue injury healing. Curr Med Chem. 2012;19:90\u20137.","journal-title":"Curr Med Chem"},{"key":"16069_CR26","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/01.RES.0000163633.10240.3b","volume":"96","author":"N Ouchi","year":"2005","unstructured":"Ouchi N, Shibata R, Walsh K. AMP-activated protein kinase signaling stimulates VEGF expression and angiogenesis in skeletal muscle. Circ Res. 2005;96:838\u201346.","journal-title":"Circ Res"},{"key":"16069_CR27","doi-asserted-by":"publisher","first-page":"104119","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"LQ Fu","year":"2020","unstructured":"Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119.","journal-title":"Cell Immunol"},{"key":"16069_CR28","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/joim.12019","volume":"273","author":"L Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273:114\u201327.","journal-title":"J Intern Med"},{"key":"16069_CR29","first-page":"91","volume":"7","author":"SH Park","year":"2001","unstructured":"Park SH, Kim KW, Lee YS, Baek JH, Kim MS, Lee YM, et al. Hypoglycemia-induced VEGF expression is mediated by intracellular Ca2+ and protein kinase C signaling pathway in HepG2 human hepatoblastoma cells. Int J Mol Med. 2001;7:91\u20136.","journal-title":"Int J Mol Med"},{"issue":"1","key":"16069_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/j.2040-4603.2014.tb00548.x","volume":"4","author":"L Rui","year":"2014","unstructured":"Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4(1):177\u201397.","journal-title":"Compr Physiol"},{"key":"16069_CR31","doi-asserted-by":"publisher","first-page":"168162","DOI":"10.1016\/j.jmb.2023.168162","volume":"435","author":"CCT Chow","year":"2023","unstructured":"Chow CCT, Kobayashi M, Kambe G, Harada H. ZBTB2 is recruited to a specific subset of HIF-1 target loci to facilitate full gene expression under hypoxia. J Mol Biol. 2023;435:168162.","journal-title":"J Mol Biol"},{"key":"16069_CR32","doi-asserted-by":"publisher","first-page":"7997","DOI":"10.1093\/nar\/gkt539","volume":"41","author":"T Arcond\u00e9guy","year":"2013","unstructured":"Arcond\u00e9guy T, Lacazette E, Millevoi S, Prats H, Touriol C. VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res. 2013;41:7997\u20138010.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"16069_CR33","doi-asserted-by":"publisher","first-page":"921","DOI":"10.18632\/oncotarget.626","volume":"3","author":"GJ Prud'homme","year":"2012","unstructured":"Prud\u2019homme GJ, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 2012;3(9):921\u201339.","journal-title":"Oncotarget"},{"key":"16069_CR34","doi-asserted-by":"publisher","first-page":"7282","DOI":"10.1128\/MCB.20.19.7282-7291.2000","volume":"20","author":"J Grunstein","year":"2000","unstructured":"Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol. 2000;20:7282\u201391.","journal-title":"Mol Cell Biol"},{"key":"16069_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12885-018-4442-2","volume":"18","author":"M Martini","year":"2018","unstructured":"Martini M, de Pascalis I, D\u2019Alessandris QG, Fiorentino V, Pierconti F, Marei HE, et al. VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma. BMC Cancer. 2018;18:553.","journal-title":"BMC Cancer"},{"key":"16069_CR36","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming XuJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119\u201327.","journal-title":"J Clin Oncol"},{"key":"16069_CR37","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/bjc.2013.69","volume":"108","author":"DW Miles","year":"2013","unstructured":"Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108:1052\u201360.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16069-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:29:43Z","timestamp":1782772183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16069-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16069"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16069-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"782"}}